Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Invests $1M in Calando Subsidiary

Premium

Arrowhead Research said this week that it has invested $1 million in its majority-owned subsidiary Calando Pharmaceuticals through the purchase of 60 million shares of preferred stock.

The companies also converted roughly $8 million in Calando debt it owed Arrowhead into equity.

With the transactions, Arrowhead said it now holds about 79 percent of Calando's outstanding equity.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.